Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Propionibacterium extract is a lysate derived from the bacterium *Propionibacterium acnes* (also known as *Cutibacterium acnes*), formulated as a topical gel for proctological and dermatological applications. [10, 17] Marketed under brand names like Emorsan®, it is used to aid in the healing of anorectal conditions such as chronic anal fissures and postoperative wounds from hemorrhoidectomy. [3, 6, 8] The mechanism of action involves creating a protective film over the skin and mucous membranes while providing local antioxidant effects. [3, 6] By scavenging reactive oxygen and nitrogen species, the extract reduces oxidative stress and inflammation, which helps to alleviate symptoms like pain, itching, and burning, and promotes the re-epithelialization and healing of tissues. [3, 9] Studies have also investigated its use for anal condylomata associated with HPV infection. [17]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on propionibacterium extract.